Pancreatic Cancer: Beyond Brca Mutations.

Autor:	Ricci V; Medical Oncology Unit, AORN 'San Pio', 82100 Benevento, Italy., Fabozzi T; Medical Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Bareschino MA; Medical Oncology Unit, AORN 'San Pio', 82100 Benevento, Italy., Barletta E; Medical Oncology Unit, AORN 'San Pio', 82100 Benevento, Italy., Germano D; Medical Oncology Unit, AORN 'San Pio', 82100 Benevento, Italy., Paciolla I; Medical Oncology Unit, AORN 'San Pio', 82100 Benevento, Italy., Tinessa V; Medical Oncology Unit, AORN 'San Pio', 82100 Benevento, Italy., Grimaldi AM; Medical Oncology Unit, AORN 'San Pio', 82100 Benevento, Italy.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2022 Dec 16; Vol. 12 (12). Date of Electronic Publication: 2022 Dec 16.
DOI:	10.3390/jpm12122076
Abstrakt:	Pancreatic cancer is the fourth-leading cause of cancer-related deaths worldwide. The outcomes in patients with pancreatic cancer remain unsatisfactory. In the current review, we summarize the genetic and epigenetic architecture of metastatic pancreatic cancer beyond the BRCA mutations, focusing on the genetic alterations and the molecular pathology in pancreatic cancer. This review focuses on the molecular targets for the treatment of pancreatic cancer, with a correlation to future treatments. The potential approach addressed in this review may lead to the identification of a subset of patients with specific biological behaviors and treatment responses.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu